Janux Therapeutics
JANX
50 hedge funds and large institutions have $381M invested in Janux Therapeutics in 2022 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 16 increasing their positions, 12 reducing their positions, and 8 closing their positions.
3,729% more call options, than puts
Call options by funds: $804K | Put options by funds: $21K
33% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 12
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
2% more funds holding
Funds holding: 49 → 50 (+1)
2% less capital invested
Capital invested by funds: $388M → $381M (-$7.13M)
6.16% less ownership
Funds ownership: 75.66% → 69.5% (-6.2%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$4.41M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$1.54M |
| 3 |
VIA
Vident Investment Advisory
Alpharetta,
Georgia
|
+$842K |
| 4 |
Millennium Management
New York
|
+$584K |
| 5 |
E
Ergoteles
New York
|
+$462K |
Top Sellers
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$30.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.39M |
| 3 |
BlackRock
New York
|
-$2.16M |
| 4 |
Morgan Stanley
New York
|
-$1.81M |
| 5 |
Cerity Partners
New York
|
-$1.43M |
JANX Hedge Fund Activity: Q4 2022 in Review
50 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Janux Therapeutics (JANX) for Q4 2022, worth a combined $381M — down 1.8% from $388M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new JANX positions and 8 closed out — a net gain of 1 holder — while 16 added to existing stakes and 12 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $4.41M. The largest seller was Janus Henderson Group, cutting an estimated $30.5M.
- 50 institutional investors held Janux Therapeutics (JANX) as of Q4 2022, up from 49 in Q3 2022.
- Funds reported $381M of Janux Therapeutics stock for Q4 2022, down 1.8% quarter-over-quarter.
- 9 funds opened new Janux Therapeutics positions in Q4 2022 and 8 closed out, a net change of +1 holder.
- The largest Janux Therapeutics buyer in Q4 2022 was Adage Capital Partners, an estimated $4.41M added.
- The largest Janux Therapeutics seller in Q4 2022 was Janus Henderson Group, an estimated $30.5M sold.
Based on aggregated 13F filings for Q4 2022.